Capabilities of sugar-lowering therapy in women with decompensated type 2 diabetes mellitus

Terapevticheskii Arkhiv

Volumn 82, Issue 8, 2010, Pages 34-41

  Onuchin, S G ^a   Elsukova, O S ^a   Solovyev, O V ^a   Onuchina, E L ^a  

^a KIROV STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Sugar lowering therapy; Type 2 diabetes mellitus; Women

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; INSULIN; METFORMIN;

ARTICLE; BLOOD; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77957122095     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. The DECODE Study group: Age and sex specific prevalences of diabetes and glucose regulation in 13 European cohorts. Diabet. Care 2003; 6: 61-69.
2. Peterson S., Peto V., Rayner M. et al. European cardiovascular disease statistics. 2-nd ed. London: British heart foundation; 2005.
3. Del Prato S., Wishner W., Gromada J. et al. Beta-cell mass plasticity in type 2 diabetes. Diabet. Obes. Metab. 2004; 6: 319-331.
4. Kahn S. E. Regulation of (3-cell function in vivo: from health to disease. Diabet. Rev. 1996; 4: 372-389.
5. Nathan D. M., Buse J. B., Davidson M. B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association of the Study of Diabetes. Diabet. Care 2008; 31: 1-11.
6. Lusthman P. J., Anderson R. J., Freedland K. E. et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabet. Care 2000; 23: 434-442.
7. Stramba-Badiale M., Priori S. G. Gender-specific prescription for cardiovascular diseases? Eur. Heart J. 2005; 26 (16): 1571-1572.
8. Jochmann N., Stangl K., Garbe E. et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular disease. Eur. Heart J. 2005; 26 (16): 1585-1595.
9. Wallace T., Levy J., Matthews D. Use and abuse of HOMA modeling. Diabet. Care 2004; 27: 1487-1495.
10. Ganau A., Devereux R., Roman M. J. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol. 1992; 19: 1550-1558.
11. Paulus W. J., Tschópe C., Saderson J. E. et al. How to diagnose diastolic heart failure? A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 2007; 28: 2539-2550.
12. Stevens R. J., Kothari V., Adler A. I. et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci. 2001; 101: 671-679.
13. Ware J. E., Snow K. K., Kosinsky M., Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
14. Ware J. E. Measuring patients views: the optimum outcome measure. SF 36: a valid, reliable assessment of health from the patient's point of view. Br. Med. J. 1993; 306: 1429-1430.
15. Myers J. K., Weissman M. M. Use of a self-report symptom scale to detect depression in a community sample. Am. J. Psychiatry 1980; 137: 1081-1084.